Based on the UCB SA ADR stock forecast from 0 analysts, the average analyst target price for UCB SA ADR is not available over the next 12 months. UCB SA ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of UCB SA ADR is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, UCB SA ADR’s stock price was USD 98.04. UCB SA ADR’s stock price has changed by +1.83% over the past week, +7.70% over the past month and +165.19% over the last year.
No recent analyst target price found for UCB SA ADR
No recent average analyst rating found for UCB SA ADR
Company Overview UCB SA ADR
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. Read Less
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Croh...Read More
Frequently Asked Questions About UCB SA ADR (UCBJY) Stock
Stock Target Advisor's fundamental analysis for UCB SA ADR's stock is Neutral.
UCBJY stock's dividend yield is 0.74%.
Our analysis grades UCBJY stock's dividend yield at F. This means that UCBJY stock's dividend yield is above 30% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this UCBJY may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on UCBJY's stock to indicate what its average analyst target is.
UCBJY stock's Price/Earning ratio is 146.33.
Our analysis grades UCBJY stock's Price / Earning ratio at F. This means that UCBJY stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this UCBJY may be a overvalued for its sector.
The last closing price of UCBJY's stock was USD 98.04.
The most recent market capitalization for UCBJY is USD 37.20B.
Unfortunately we do not have enough analyst data on UCBJY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains UCB SA ADR's stock.
As per our most recent records UCB SA ADR has 9,000 Employees.
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About UCB SA ADR (UCBJY) Stock
Stock Target Advisor's fundamental analysis for UCB SA ADR's stock is Neutral.
UCBJY stock's dividend yield is 0.74%.
Our analysis grades UCBJY stock's dividend yield at F. This means that UCBJY stock's dividend yield is above 30% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this UCBJY may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on UCBJY's stock to indicate what its average analyst target is.
UCBJY stock's Price/Earning ratio is 146.33.
Our analysis grades UCBJY stock's Price / Earning ratio at F. This means that UCBJY stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this UCBJY may be a overvalued for its sector.
The last closing price of UCBJY's stock was USD 98.04.
The most recent market capitalization for UCBJY is USD 37.20B.
Unfortunately we do not have enough analyst data on UCBJY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains UCB SA ADR's stock.
As per our most recent records UCB SA ADR has 9,000 Employees.
